Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Mylan Inc    

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Mylan Inc. : Before the Bell Scans of MYL, TEVA, COV, VRX, and ZTS

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/09/2013 | 08:50am CET

StockCall.com Provides Stock Research on Mylan Inc., Teva Pharmaceutical Industries Ltd, Covidien plc, Valeant Pharmaceuticals International Inc., and Zoetis Inc.

New York City, New York -- (May 09, 2013)

Equity markets edged higher on Wednesday after struggling initially. It was yet another historic day as the Dow Jones and the S&P 500 closed at fresh all-time high levels. Market sentiment was lifted by better-than-expected trade data from China. Improving global economic outlook coupled with ultra-loose monetary policies from developed world central banks have boosted investors? risk appetite. Yesterday, the healthcare sector was among the best performers in the S&P 500. Among the major movers in this sector were Mylan Inc. (NASDAQ: MYL), Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), Covidien Plc (NYSE: COV), Vertex Pharmaceuticals International Inc. (NYSE: VRX), and Zoetis Inc. (NYSE: ZTS). StockCall has taken an interest in these companies and you can now sign up to download the free technical research on MYL, TEVA, COV, VRX, and ZTS at

www.stockcall.com/registration

Mylan Inc.?s shares edged lower in trading on Wednesday. The stock traded between $29.30 and $29.93 before finishing the day 1.21% lower at $29.33 on volume of 4.41 million. Despite the losses yesterday, Mylan?s shares have gained nearly 1.50% in the last three trading sessions. Year-to-date, the stock has gained more than 6.80%, underperforming the broad market. Shares of MYL are currently trading more than 6% below their 52-week high. Sign up today to read the free research report on MYL at

www.StockCall.com/MYL050913.pdf

Shares of Teva Pharmaceutical Industries Ltd. edged higher in yesterday?s trading session; however, the gains were limited. The stock closed 0.18% higher at $38.42 on volume of 2.94 million. Teva Pharmaceutical?s shares are currently trading close to their 52-week low of $38.33. The stock is also trading below its 50-day and 200-day moving averages which is a bearish signal. However, the stock?s MACD has just crossed above the signal line which suggests that market sentiment has turned bearish. Register to download the free technical analysis on TEVA at

www.StockCall.com/TEVA050913.pdf

Shares of Covidien Plc edged higher on Wednesday, tracking gains in the broad market. The stock touched an intraday high of $65.88 before finishing the day 0.98% higher at $65.88 on volume of 2.89 million. Covidien?s shares have gained nearly 2.40% in the last three trading sessions. The stock has seen a series of highs over the past week which is a bullish signal. The positive trend is further confirmed by recent volume activity, and the stock?s MACD chart. Free report on COV can be accessed by registering at

www.StockCall.com/COV050913.pdf

Valeant Pharmaceuticals International Inc.?s shares struggled in yesterday?s trading session. The stock ended the day 0.28% lower at $73.86 on volume of 713,719. The company?s shares are currently trading close to their 52-week high of $76.57. The stock has gained nearly 23.60% so far in 2013 as compared to a gain of nearly 14.50% for the S&P 500. The stock is currently trading above its 50-day and 200-day moving averages.Register withStockCall and download the research on VRX for free at

www.StockCall.com/VRX050913.pdf

Shares of Zoetis Inc. rose in trading on Wednesday. The stock touched an intra-day high of $33.44 before finishing the day 1.16% higher at $33.26 on volume of 1.03 million. Zoetis?shares have underperformed the S&P 500 so far in 2013, gaining nearly 7.50%. The stock?s MACD is currently trading above the signal line and the zero-line which is a bullish signal. Shares of ZTS are trading nearly 6% below their 52-week high. Read the full free research on ZTS by signing up to StockCall at

www.StockCall.com/ZTS050913.pdf

About StockCall.com

StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines. Sign up today to talk to our financial analyst at

www.stockcall.com

Contact Person:

William T. Knight

Email: info@stockcall.com

Contact Number: (646) 396-9857 (9:00 am EST ? 01:30 pm EST)


© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MYLAN INC
12/05 MYLAN : Rosen Law Firm Reminds Mylan N.V. Investors of Important Dec. 12 Deadlin..
12/02 MYLAN NV : DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors..
12/02 Pharma execs weigh in on possible changes under Trump
12/01 MYLAN : The Law Offices of Howard G. Smith Announces the Filing of a Securities ..
12/01 MYLAN : Commitment to Stemming the Tide of HIV/AIDS as Strong as Ever
11/29 MYLAN : Signs Sub-license Agreement with the Medicines Patent Pool to Increase A..
11/28 MYLAN : Signs Sub-license Agreement with the Medicines Patent Pool to Increase A..
11/25 Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $1..
11/22 MYLAN NV : SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Invest..
11/21 MYLAN : declines Senate committee request to testify about EpiPen
More news
Sector news : Pharmaceuticals - NEC
09:19pDJNovo Nordisk Pledges to Limit Price Increases in U.S. for Its Drugs
05:58pDJSANOFI : Big Pharma, Short on Blockbusters, Outsources the -2-
05:58pDJSANOFI : Big Pharma, Short on Blockbusters, Outsources the Science
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
2015 Mylan (MYL) Heather M. Bresch on Q4 2014 Results - Earnings Call Transcript
2015 Mylan Q4 revenues up 15%, Specialty up 38%
2015 Mylan (MYL) Q4 2014 Results - Earnings Call Webcast
2015 Mylan EPS in-line, beats on revenue
2015 Notable earnings after Monday?s close
Advertisement
Financials ($)
Sales 2016 11 021 M
EBIT 2016 3 195 M
Net income 2016 1 054 M
Debt 2016 11 500 M
Yield 2016 -
P/E ratio 2016 19,09
P/E ratio 2017 9,75
EV / Sales 2016 2,77x
EV / Sales 2017 2,36x
Capitalization 19 077 M
More Financials
Chart MYLAN INC
Duration : Period :
Mylan Inc Technical Analysis Chart | US6285301072 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 50,9 $
Spread / Average Target 43%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Heather M. Bresch Chief Executive Officer & Executive Director
Rajiv Malik President & Executive Director
Robert J. Coury Executive Chairman
Kenneth Scott Parks Chief Financial Officer
Wendy Cameron Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MYLAN INC-1.66%19 077
JOHNSON & JOHNSON8.98%304 536
PFIZER INC.-2.14%191 699
ROCHE HOLDING LTD.-19.65%189 885
NOVARTIS AG-20.79%180 598
MERCK & CO., INC.15.73%166 118
More Results